We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

145 hedge funds and large institutions have $1.85B invested in Apellis Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 49 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more call options, than puts

Call options by funds: $4.72M | Put options by funds: $3.67M

17% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 18

2% more funds holding

Funds holding: 142 → 145 (+3)

1.17% more ownership

Funds ownership: 81.03% → 82.2% (+1.2%)

2% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 49

7% less capital invested

Capital invested by funds: $2B → $1.85B (-$149M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
145
Holders Change
+3
Holders Change %
+2.11%
% of All Funds
2.93%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
21
Increased
50
Reduced
49
Closed
18
Calls
$4.72M
Puts
$3.67M
Net Calls
+$1.05M
Net Calls Change
-$424K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$24.9M
2
Jennison Associates
Jennison Associates
New York
+$21.2M
3
APM
Avidity Partners Management
Texas
+$18.6M
4
JP Morgan Chase
JP Morgan Chase
New York
+$18M
5
Norges Bank
Norges Bank
Norway
+$16.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity International
Fidelity International
Bermuda
-$25.4M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$25.1M
3
EP
Eversept Partners
New York
-$10.1M
4
Two Sigma Investments
Two Sigma Investments
New York
-$7.13M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
Handelsbanken Fonder
101
Handelsbanken Fonder
Sweden
$386K – – –
SEC
102
Seven Eight Capital
New York
$355K +$352K +11,769 New
WCM
103
Weld Capital Management
New York
$343K +$339K +11,360 New
AIM
104
Aigen Investment Management
New York
$311K +$308K +10,308 New
VEA
105
Virtus ETF Advisers
New York
$300K -$40.4K -1,352 -12%
RJFSA
106
Raymond James Financial Services Advisors
Florida
$297K +$49.5K +1,657 +20%
Public Employees Retirement Association of Colorado
107
Public Employees Retirement Association of Colorado
Colorado
$294K – – –
AB
108
Amalgamated Bank
New York
$282K -$8.43K -282 -3%
Citigroup
109
Citigroup
New York
$278K -$1.75M -58,578 -86%
DA
110
Duality Advisers
Florida
$265K +$263K +8,800 New
Los Angeles Capital Management
111
Los Angeles Capital Management
California
$255K +$252K +8,440 New
Zurich Cantonal Bank
112
Zurich Cantonal Bank
Switzerland
$245K – – –
BC
113
Birchview Capital
Vermont
$241K – – –
MML Investors Services
114
MML Investors Services
Massachusetts
$229K – – –
QSS
115
Quantitative Systematic Strategies
Florida
$228K +$226K +7,554 New
OC
116
Oppenheimer & Co
New York
$225K +$223K +7,449 New
AAMU
117
Amundi Asset Management US
Massachusetts
$220K +$111K +3,700 +103%
AC
118
Athanor Capital
New York
$203K -$95.2K -3,187 -32%
PNC Financial Services Group
119
PNC Financial Services Group
Pennsylvania
$179K +$28.1K +940 +19%
AIP
120
Ameritas Investment Partners
Nebraska
$160K – – –
FMT
121
First Mercantile Trust
Tennessee
$137K +$30 +1 +0%
Canada Life
122
Canada Life
Manitoba, Canada
$121K -$208K -6,962 -63%
IAS
123
IMA Advisory Services
Colorado
$121K – – –
Pacer Advisors
124
Pacer Advisors
Pennsylvania
$102K +$101K +3,391 New
TRCT
125
Tower Research Capital (TRC)
New York
$91K -$169K -5,647 -65%
3 4
5
6 7

APLS Hedge Fund Activity: Q3 2020 in Review

145 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2020, worth a combined $1.85B — down 7.4% from $2B a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new APLS positions and 18 closed out — a net gain of 3 holders — while 50 added to existing stakes and 49 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $24.9M. The largest seller was Fidelity International, cutting an estimated $25.4M.

  • 145 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2020, up from 142 in Q2 2020.
  • Funds reported $1.85B of Apellis Pharmaceuticals stock for Q3 2020, down 7.4% quarter-over-quarter.
  • 21 funds opened new Apellis Pharmaceuticals positions in Q3 2020 and 18 closed out, a net change of +3 holders.
  • The largest Apellis Pharmaceuticals buyer in Q3 2020 was Citadel Advisors, an estimated $24.9M added.
  • The largest Apellis Pharmaceuticals seller in Q3 2020 was Fidelity International, an estimated $25.4M sold.

Based on aggregated 13F filings for Q3 2020.